Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 6/20 | 0.48 |
| ▸ | EGFR | P00533 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14115009 | 0.88 | EGFR (0.47) | HTTSMN1; SMN2ALDH1A1TNFKDR | |
| SCHEMBL25680896 | 0.81 | NTSR1 (0.50) | HTTSMN1; SMN2ALDH1A1KDRKDM4E | |
| SCHEMBL294809 | 0.79 | SMN1; SMN2 (0.56) | HTTSMN1; SMN2ALDH1A1TNFKDR | |
| SCHEMBL29532044 | 0.79 | SMN1; SMN2 (0.56) | HTTSMN1; SMN2ALDH1A1TNFKDR | |
| SCHEMBL11320298 | 0.77 | SMN1; SMN2 (0.55) | HTTSMN1; SMN2ALDH1A1TNFKDR | |
| SCHEMBL3318468 | 0.77 | SMN1; SMN2 (0.55) | HTTSMN1; SMN2ALDH1A1TNFKDR | |
| SCHEMBL16521332 | 0.77 | SMN1; SMN2 (0.52) | HTTSMN1; SMN2ALDH1A1KDREGFR | |
| Propanol SCHEMBL28411721 | 0.76 | HTT (0.60) | HTTSMN1; SMN2ALDH1A1TNFKDR | |
| SCHEMBL30636665 | 0.76 | EGFR (0.57) | HTTSMN1; SMN2ALDH1A1TNFKDR | |
| SCHEMBL2171367 | 0.76 | EGFR (0.57) | HTTSMN1; SMN2ALDH1A1TNFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-08-25 | — | — | US | disclosed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2007144699-A2 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | TORRENT PHARMACEUTICALS LIMITED (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | HTT 3161/4885SMN1; SMN2 3354/4885ALDH1A1 4309/4885 |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | AXL, TYRO3, FLT3 | HTT 3222/4885SMN1; SMN2 4804/4885ALDH1A1 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.